The research, published online in Nature Medicine, suggests a new approach to individualizing the treatment of chronic pain. Scientists identified a gene that encodes the P2X7 pain receptor, discovering that a single amino acid change in P2X7 controls sensitivity to nerve damage and inflammation.
“The amino-acid change is known to affect only one function of P2X7 receptors — the forming of pores that permit large molecules to pass through — while leaving intact the other function, of allowing much tinier ions to flow through,” the report said. Researchers then used a peptide that targets pore formation and found that pain behaviors were drastically reduced.
Related Articles on Pain Management:
Interventional Pain Management Physician Dr. John Hume Joins Houston’s KSF Orthopaedic Center
Tennessee Pain Bill Faces Opposition from Lawmakers, Physicians
Editorial: Kentucky Medical Association President Opposes Current Pain Clinic Legislation
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
